Evidence map›Paper›PMID 40864772›Full record

ArticleCurrent issues in molecular biology2025

Obesity-Induced MASLD Is Reversed by Capsaicin via Hepatic TRPV1 Activation.

Padmamalini Baskaran, Ryan Christensen, Kimberley D Bruce, Robert H Eckel

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Padmamalini BaskaranDepartment of Pharmaceutical Sciences, College of Pharmacy, Howard University College of Pharmacy, Washington, DC 20059, USA.ORCID 0000-0001-8851-1486
Ryan ChristensenMolecular Signaling Laboratory, Department of Pharmaceutical Sciences, College of Pharmacy, University of Wyoming, Laramie, WY 82071, USA.
Kimberley D BruceAnschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA.
Robert H EckelAnschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA.

Funding

American Association of Colleges of Pharmacy New Investigator Award
6 · The paper itself

Abstract

BACKGROUND AND

objectivesMetabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive liver disorder associated with metabolic risk factors such as obesity, type 2 diabetes, and cardiovascular disease. If left untreated, the accumulation of excess hepatic fat can lead to inflammation, fibrosis, cirrhosis, hepatocellular carcinoma, and ultimately liver failure. Capsaicin (CAP), the primary pungent compound in chili peppers, has previously been shown to prevent weight gain in high-fat diet (HFD)-induced obesity models. In this study, we investigated the potential of dietary CAP to prevent HFD-induced MASLD.

methodsC57BL/6 mice were fed an HFD (60% kcal from fat) with or without 0.01% CAP supplementation for 26 weeks. We evaluated CAP's effects on hepatic fat accumulation, inflammation, and mitochondrial function to determine its role in preventing MASLD.

resultsCAP acts as a potent and selective agonist of the transient receptor potential vanilloid 1 (TRPV1) channel. We confirmed TRPV1 expression in the liver and demonstrated that CAP activates hepatic TRPV1, thereby preventing steatosis, improving insulin sensitivity, reducing inflammation, and enhancing fatty acid oxidation. These beneficial effects were observed in wild-type but not in TRPV1 knockout mice. Mechanistically, CAP-induced TRPV1 activation promotes calcium influx and activates AMPK, which leads to SIRT1-dependent upregulation of PPARα and PGC-1α, enhancing mitochondrial biogenesis and lipid metabolism.

conclusionsOur findings suggest that dietary CAP prevents MASLD through TRPV1 activation. TRPV1 signaling represents a promising therapeutic target for the prevention and management of MASLD in individuals with metabolic disorders.

Indexed as

diabetesfatty acid oxidationinsulin resistanceMASLDmitochondriaobesityTRPV1

Identifiers

PMID40864772
PMCPMC12384517

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.